Magrolimab and Pembrolizumab Combination Study in Hodgkin Lymphoma Initiated
A clinical trial is underway to evaluate the safety and efficacy of magrolimab combined with pembrolizumab in relapsed or refractory classic Hodgkin lymphoma.
Asset / Drug
Drug and asset intelligence for Magrolimab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.